免疫检查点治疗时代肾细胞癌的预后模型
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.
作者信息
Parosanu Andreea, Stanciu Ioana Miruna, Pirlog Cristina, Orlov Slavu Cristina, Cotan Horia, Iaciu Cristian, Popa Ana Maria, Olaru Mihaela, Moldoveanu Oana, Catalin Baston, Nitipir Cornelia
机构信息
Oncology, Elias Emergency University Hospital, Bucharest, ROU.
Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU.
出版信息
Cureus. 2022 Oct 29;14(10):e30821. doi: 10.7759/cureus.30821. eCollection 2022 Oct.
Abstract
With recent advances in oncology, immune checkpoint inhibitors (ICIs) have become a milestone in immuno-oncology. Unfortunately, although ICIs have demonstrated improved clinical efficacy in a broad spectrum of cancers, many patients do not respond to this newer therapy. As a result, it is crucial to identify predictive factors of response to immunotherapy in patients with kidney cancer. This review discusses the research investigating potential biomarkers of response to ICIs in renal cell carcinoma.
摘要
随着肿瘤学领域的最新进展，免疫检查点抑制剂（ICI）已成为免疫肿瘤学的一个里程碑。不幸的是，尽管ICI在多种癌症中已显示出改善的临床疗效，但许多患者对这种新疗法没有反应。因此，识别肾癌患者免疫治疗反应的预测因素至关重要。本综述讨论了关于肾细胞癌中ICI反应潜在生物标志物的研究。
相似文献
1
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.免疫检查点治疗时代肾细胞癌的预后模型
Cureus. 2022 Oct 29;14(10):e30821. doi: 10.7759/cureus.30821. eCollection 2022 Oct.
2
Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.肾细胞癌中免疫检查点抑制剂反应和耐药的生物标志物
Cancers (Basel). 2023 Jun 12;15(12):3159. doi: 10.3390/cancers15123159.
3
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?免疫检查点抑制剂在肿瘤学中的应用与 AKI 的发生：我们处于什么位置？
Front Immunol. 2020 Oct 8;11:574271. doi: 10.3389/fimmu.2020.574271. eCollection 2020.
4
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.肠道微生物群在转移性肾细胞癌免疫调节中的作用。
Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122714. doi: 10.1177/17588359221122714. eCollection 2022.
5
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.晚期泌尿生殖系统恶性肿瘤患者接受免疫检查点抑制剂治疗的结局特征。
Urol Oncol. 2021 Jul;39(7):437.e1-437.e9. doi: 10.1016/j.urolonc.2021.01.006. Epub 2021 Jan 23.
6
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.免疫相关不良事件作为免疫检查点抑制剂治疗转移性肾细胞癌患者的临床生物标志物。
Oncologist. 2021 Oct;26(10):e1742-e1750. doi: 10.1002/onco.13868. Epub 2021 Jul 8.
7
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis.免疫检查点抑制剂治疗转移性肾细胞癌的血液学预后因子：荟萃分析。
Immunotherapy. 2022 Jun;14(9):709-725. doi: 10.2217/imt-2021-0207. Epub 2022 Apr 25.
8
Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.免疫检查点抑制剂治疗非小细胞肺癌的稳健预测。
Front Immunol. 2021 Apr 13;12:646874. doi: 10.3389/fimmu.2021.646874. eCollection 2021.
9
Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中的免疫检查点抑制剂。
Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247.
10
Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.晚期肾细胞癌患者接受免疫检查点抑制剂治疗的完全缓解：一项随机临床试验的荟萃分析。
Urol Oncol. 2020 Oct;38(10):798.e17-798.e24. doi: 10.1016/j.urolonc.2020.06.021. Epub 2020 Aug 7.
本文引用的文献
1
Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.预后营养指数预测接受免疫检查点抑制剂治疗的癌症患者的反应和预后：一项系统评价和荟萃分析。
Front Nutr. 2022 Jul 22;9:823087. doi: 10.3389/fnut.2022.823087. eCollection 2022.
2
RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era.肾细胞癌真实世界数据：免疫治疗时代的预后因素与风险分层
Cancers (Basel). 2022 Jun 26;14(13):3127. doi: 10.3390/cancers14133127.
3
Prognostic impact of prognostic nutritional index on renal cell carcinoma: A meta-analysis of 7,629 patients.预后营养指数对肾细胞癌预后的影响：7629 例患者的荟萃分析。
PLoS One. 2022 Mar 21;17(3):e0265119. doi: 10.1371/journal.pone.0265119. eCollection 2022.
4
The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.肥胖在肿瘤学中的作用具有双重性，它既能促进癌症的发生，又能增强抗肿瘤免疫治疗。
J Biomed Sci. 2022 Feb 14;29(1):12. doi: 10.1186/s12929-022-00796-0.
5
External Validation of the Prognostic Value of an Immune-Associated Gene Panel for Clear Cell Renal Cell Carcinomas.免疫相关基因panel对透明细胞肾细胞癌预后价值的外部验证
Front Cell Dev Biol. 2021 Dec 23;9:794840. doi: 10.3389/fcell.2021.794840. eCollection 2021.
6
promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma.启动子低甲基化是初诊时的一个负预后生物标志物，但在透明细胞肾细胞癌中，它预测对基于抗 PD-1 的免疫治疗有反应和良好的结果。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002949.
7
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.嗜酸性粒细胞计数作为预测纳武利尤单抗治疗肾细胞癌反应的相关预后标志物：一项回顾性研究。
Cancer Med. 2021 Oct;10(19):6705-6713. doi: 10.1002/cam4.4208. Epub 2021 Aug 18.
8
Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview.肾细胞癌脑转移的预后因素及当前治疗策略：综述
Cancers (Basel). 2021 Apr 27;13(9):2114. doi: 10.3390/cancers13092114.
9
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.琥珀酸脱氢酶缺陷型肾细胞癌的全面分子特征分析及治疗反应
Clin Cancer Res. 2021 May 15;27(10):2910-2919. doi: 10.1158/1078-0432.CCR-20-4367. Epub 2021 Mar 3.
10
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
Zotero 插件